1
|
Lacouture ME, Lang JE, Chawla S, Goldfarb S, Markova A, Pan A, Cavanna-Mast RM, Mast P, Savoie C, diZerega G. Abstract PS14-05: Phase 1/2 clinical trial of a topical submicron particle paclitaxel (SOR007) for the treatment of cutaneous metastases. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps14-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cutaneous Metastases (CM) are an infrequent presentation of advanced solid tumors and are usually associated with symptoms of pain, pruritus, and secondary infections, all of which negatively affect quality of life and result in additional morbidity. Systemic chemotherapy, advanced wound care, topical agents, cryo-, electro-, photodynamic-, laser and intralesional therapies have been limited by inconsistent efficacy, inconvenience, or toxicity. In this open-label phase 1/2 clinical trial, submicron particle paclitaxel in an anhydrous base (SOR007) was evaluated for topical treatment of CM from breast cancer (n=21), leiomyosarcoma (n=1) and Paget’s disease (n=1). Previously, in vitro, in vivo, and clinical studies demonstrated penetration of paclitaxel into the dermis with the silicone-based anhydrous producing subtoxic plasma levels in GLP toxicology studies and early clinical trials.
Trial Design: The phase 1/2 open label trial evaluated 3 doses of SOR007 (0.15%, 1.0%, 2.0%). Approximately 0.5 grams (1 FTU) of SOR007 per 50 cm2 treatment area was applied BID during a 3+3 dose-rising phase for 28 days (n=10) or a dose-expansion phase at 2% strength BID for 28 days (n=2) or 56 days (n=11) unless discontinuation became necessary due to clinical course of the underlying disease.
Results: At least one eligible lesion was treated per subject and classified per RECIST 1.1. In the 28-day application group, 10 subjects were treated and in the 56-day application group, 11 subjects were treated. Lesion response is summarized in the table below for data to date. Lesion response was evaluated within 2 weeks of last treatment day in most subjects.
Conclusions: SOR007 was safe when applied to CM lesions. SOR007 resulted in decreased lesion progression or reduced lesion area in the majority of CM subjects. These clinical benefits became more consistent and pronounced at 2% strength with longer treatment suggesting a dose/duration response. Lesion pain reduction is also suggested from the study. Additional clinical research with more subjects and longer treatment periods is in the early planning stage.
Lesion ResponseLesion response by SUBJECTLesion response by SUBJECTLesion response by INDIVIDUAL LESIONLesion response by INDIVIDUAL LESIONDose-rising 0.15%, 1%, 2% & Dose expansion 2%Dose-expansion 2%Dose-rising 0.15%, 1%, 2% & Dose expansion 2%Dose-expansion 2%BID x 28 daysBID x 56 daysBID x 28 daysBID x 56 daysN (subjects or lesions)8111823Complete Response0% (0/8)9.1% (1/11)5.5% (1/18)26% (6/23)Objective Response Rate13% (1/8)45% (5/11)17% (3/18)43% (10/23)No lesion progression in evaluable subjects 63% (5/8)82% (9/11)61% (11/18)83% (19/23)
Citation Format: Mario E Lacouture, Julie E Lang, Sant Chawla, Shari Goldfarb, Alina Markova, Alexander Pan, Rose Marie Cavanna-Mast, Peter Mast, Christopher Savoie, Gere diZerega. Phase 1/2 clinical trial of a topical submicron particle paclitaxel (SOR007) for the treatment of cutaneous metastases [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-05.
Collapse
Affiliation(s)
| | - Julie E Lang
- 2USC/Norris Comprehensive Cancer Center, Los Angeles, CA
| | - Sant Chawla
- 3Sarcoma Oncology Research Center, Santa Monica, CA
| | | | - Alina Markova
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | - Alexander Pan
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | | |
Collapse
|
2
|
Mullany S, Miller DS, Robison K, Levinson K, Lee YC, Yamada SD, Walker J, Markman M, Marin A, Mast P, diZerega G. Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery. Gynecol Oncol Rep 2020; 34:100627. [PMID: 32953961 PMCID: PMC7486435 DOI: 10.1016/j.gore.2020.100627] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 08/13/2020] [Accepted: 08/18/2020] [Indexed: 01/30/2023] Open
Abstract
Patients with ovarian cancer were treated with intraperitoneal submicron particle paclitaxel after debulking surgery. Following surgery, patients received IV chemotherapy without evidence of enhanced systemic toxicity. By RECIST 1.1 criteria, 66% of patients had progression free survival at 6 months and 1-year following surgery.
Submicron particles (~800 nm) of paclitaxel (SPP) contain 1–2 billion molecules of pure drug that release tumoricidal levels of paclitaxel over many weeks. This study compared two dose-levels of SPP instilled into the peritoneal cavity (IP) in 200 ml of saline post-cytoreductive surgery. Eligible patients with primary (n = 6) or recurrent (n = 4) epithelial ovarian cancer who underwent complete cytoreductive surgery were enrolled to receive a single instillation of IP SPP followed by standard IV carboplatin and paclitaxel. Endpoints were PFS and evaluation of treatment emergent adverse events. Clinical response was determined by symptoms, physical exams, CT scans, and serum CA-125 measurements. Of the 24 subjects screened, 10 were enrolled and received treatment: seven patients received 100 mg/m2 and three received 200 mg/m2. Seven subjects completed the 12-month follow-up period. Six patients were evaluable due to one subject who had unevaluable scans throughout the follow-up period and was thus excluded from PFS determination. Upon completion of planned chemotherapy post-SPP instillation, the PFS at 6 months was 66% (4/6) and at 12-months 66% (4/6) using RECIST 1.1. One subject had a complete response at the end of IV treatment but died (unrelated to study treatment) before PFS evaluation. There was one case of incision dehiscence and one case of vaginal cuff leakage after surgery. This pilot study supports further evaluation of IP SPP to treat peritoneal carcinomas.
Collapse
Affiliation(s)
- Sally Mullany
- University of Minnesota Medical Center, 2450 Riverside Ave, Minneapolis, MN 55454, USA
| | - David Scott Miller
- University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
| | - Katina Robison
- Women & Infants Hospital, 101 Dudley St, Providence, RI 02905, USA
| | - Kimberly Levinson
- Johns Hopkins Gynecologic Oncology at GBMC, 6569 Charles St #306, Towson, MD 21204, USA
| | - Yi-Chun Lee
- SUNY DownState Medical Center, 450 Clarkson Ave, Brooklyn, NY 11203, USA
| | - S Diane Yamada
- University of Chicago Medical Center, 5841 S Maryland Ave, Chicago, IL 60637, USA
| | - Joan Walker
- University of Oklahoma, Stephenson Cancer Center, 800 NE 10th St, Oklahoma City, OK 73104, USA
| | - Maurie Markman
- Cancer Treatment Centers of America, 1331 E Wyoming Ave, Philadelphia, PA 19124, USA
| | - Alyson Marin
- US Biotest Inc., 231 Bonetti Dr # 240, San Luis Obispo, CA 93401, USA
| | - Peter Mast
- US Biotest Inc., 231 Bonetti Dr # 240, San Luis Obispo, CA 93401, USA
| | - Gere diZerega
- US Biotest Inc., 231 Bonetti Dr # 240, San Luis Obispo, CA 93401, USA.,NanOlogy, 3909 Hulen St, Fort Worth, TX 76107, USA
| |
Collapse
|
3
|
Mullany SA, Miller DS, Robison K, Levinson K, Lee YC, Yamada SD, Walker JL, Markman M, Marin A, Mast P, Dizerega G. Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e18046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18046 Background: Although advances in chemotherapy, cytoreductive surgery, and maintenance therapy (SOC) improved PFS for high grade epithelial ovarian cancer, > 20% of patients relapse during the first 6 months and 60% relapse after 6 months. Submicron particles (~800 nm) of paclitaxel (SPP) contain 1-2 billion molecules of pure drug that release tumoricidal levels of paclitaxel over many weeks. In a previous trial, percutaneous instillations of SPP in nonsurgical patients with intraperitoneal cancer were associated with reduced systemic and local toxicity as compared to standard chemotherapy regimens. (Williamson et al Cancer Chemo Pharm (2015) 75:1075). Methods: This study compared two dose-levels of IP SPP instilled in 200 ml of saline post-cytoreductive surgery. Eligible patients with primary (n = 6) or recurrent (n = 4) epithelial ovarian cancer who underwent complete cytoreductive surgery were enrolled to receive a single instillation of IP SPP followed by standard IV carboplatin and paclitaxel. Endpoints were PFS and evaluation of treatment-emergent adverse events. Clinical response was determined by CT scans and serum CA-125 measurements. Results: Of the 24 subjects screened, 10 were enrolled and received treatment: seven patients received 100 mg/m2 and three received 200 mg/m2. For analysis purposes, 7 out of 10 subjects were evaluable (1 withdrew, 1 died unrelated to study drug during IV treatment and 1 was unevaluable). Upon completion of planned chemotherapy post-SPP instillation, the PFS at 6 months was 66% (4/6) and at 12-months 66% (4/6) using RECIST 1.1. One subject had a complete response at the end of IV treatment, but died (unrelated to study treatment) before PFS evaluation. There was one case of incision dehiscence and one case of vaginal cuff leakage after surgery. Conclusions: This pilot study supports further evaluation of IP SPP to treat peritoneal carcinomas. Clinical trial information: NCT03029585.
Collapse
Affiliation(s)
| | - David S. Miller
- The University of Texas Southwestern Medical Center, Dallas, TX
| | - Katina Robison
- Women and Infants Hospital in Rhode Island, Providence, RI
| | | | - Yi-Chun Lee
- SUNY Health Science Center at Brooklyn, Brooklyn, NY
| | - Seiko Diane Yamada
- Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL
| | - Joan L. Walker
- The University of Oklahoma Health Sciences Center, Oklahoma City, OK
| | | | | | | | | |
Collapse
|
4
|
Mast P, Rodrigueztapia MT, Daeniker L, Krejci I. Understanding MIH: definition, epidemiology, differential diagnosis and new treatment guidelines. Eur J Paediatr Dent 2013; 14:204-208. [PMID: 24295005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Molar-Incisor Hypomineralisation (MIH) is a congenital disease which increases in prevalence. It affects permanent first molars and, often to a lesser degree, permanent incisors with variable severity. The aetiology is unknown, but different hypotheses have been advanced. Differential diagnosis is mandatory not to confound MIH with other diseases. Treatment consists in a minimally invasive approach by reinforcing and protecting the existing dental structure. In more severe cases, restorative treatment may be indicated.
Collapse
Affiliation(s)
- P Mast
- Division of Cariology and Endodontology, University of Geneva, Switzerland
| | | | | | | |
Collapse
|
5
|
Geerinckx T, Huysseune A, Boone M, Claeys M, Couvreur M, De Kegel B, Mast P, Van Hoorebeke L, Verbeken K, Adriaens D. Soft Dentin Results in Unique Flexible Teeth in Scraping Catfishes. Physiol Biochem Zool 2012; 85:481-90. [DOI: 10.1086/667532] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
6
|
Gratz S, Rennen HJJM, Boerman OC, Oyen WJG, Mast P, Behr TM, Corstens FHM. 99mTc-HMPAO-labeled autologous versus heterologous leukocytes for imaging infection. J Nucl Med 2002; 43:918-24. [PMID: 12097463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023] Open
Abstract
UNLABELLED Radiolabeled autologous leukocytes are the gold standard for imaging infectious foci in patients. Good results have also been reported for radiolabeled heterologous leukocytes from noninfected donors. Until now, the 2 methods have not been directly compared. In this study, we compared the infection-imaging potential of 99mTc-hexamethylpropyleneamine oxime (HMPAO)-labeled autologous granulocytes with that of 99mTc-HMPAO-labeled granulocytes from either infected or noninfected donors in rabbits with Escherichia coli infection. METHODS The radiolabeled granulocyte preparations were studied in rabbits with an E. coli infection in the left calf muscle. The soft-tissue infections were scintigraphically visualized after injection of 18 MBq of either 99mTc-HMPAO purified autologous granulocytes or radiolabeled purified heterologous granulocytes from infected or noninfected donor rabbits. Gamma camera images were acquired at 2 min and at 1, 2, and 4 h after injection. After the last image, the rabbits were killed and uptake of the radiolabel in the dissected tissues was determined. RESULTS The 99mTc-HMPAO autologous granulocytes and heterologous granulocytes from infected donors accurately revealed the infectious focus in the calf muscle at 2 h after injection. At 4 h after injection, a significantly better (P < 0.05) delineation of the infection was established with the 99mTc-HMPAO autologous granulocytes and 99mTc-HMPAO heterologous granulocytes from the infected rabbits than with the heterologous granulocytes from noninfected donors. With both cell preparations, the intensity of uptake in the infected calf muscle continuously increased until 4 h after injection. The 99mTc-HMPAO heterologous granulocytes from noninfected donors showed no significant increase in contrast after 2 h after injection. Absolute uptake in the infected calf muscle was much higher for 99mTc-HMPAO autologous granulocytes (7.81 +/- 1.21 percentage injected dose [%ID]) and 99mTc-HMPAO heterologous infected granulocytes (8.91 +/- 1.92 %ID) than for the radiolabeled heterologous noninfected granulocytes (2.32 +/- 0.75 %ID) (P < 0.04) at 4 h after injection. The ratio of infected muscle to noninfected contralateral muscle was significantly higher for 99mTc-HMPAO autologous granulocytes and 99mTc-HMPAO heterologous granulocytes from infected donors than for 99mTc-HMPAO heterologous granulocytes from noninfected donors (5.53 +/- 1.09, 3.86 +/- 0.75, and 1.86 +/- 0.31, respectively; P < 0.05). CONCLUSION For nuclear medicine imaging of infection, purified granulocytes derived from infected rabbits are superior to purified granulocytes derived from noninfected donor rabbits. In addition, autologous granulocytes gave similar results to heterologous granulocytes from infected donor rabbits, suggesting the need for intrinsic cell activation for specific granulocyte migration.
Collapse
Affiliation(s)
- Stefan Gratz
- Department of Nuclear Medicine, University Medical Center Nijmegen, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
Good experience with clam cystoplasty is reported for 28 patients (14 female), 89% of whom had a neuropathic bladder. Prolonged conservative treatment had failed in all cases. The efficacy of the operation in terms of continence, increased bladder compliance, and bladder capacity was confirmed. Complications were common and included inability to void (70%) requiring clean intermittent catheterisation (CIC), recurrent urinary tract infection (59%) and stone formation (22%). Due to these complications, further surgery was required for 44% of the patients. Although clam enterocystoplasty is an efficient way to reconstruct a functionally disturbed urinary tract, careful patient selection is essential. Lifetime follow-up and recognition of the most frequent complications is mandatory.
Collapse
Affiliation(s)
- P Mast
- Department of Urology, University Hospital, Ghent, Belgium
| | | | | | | | | |
Collapse
|
8
|
Mast P, Casselman J. [Glandular cystitis: unusual cause of a bladder mass. Clinical case and literature review]. Acta Urol Belg 1994; 62:71-6. [PMID: 7976859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We report a case of symptomatic cystitis glandularis of the trigone, causing hematuria and a vesical mass. Treatment consisted of transurethral resection of the lesion, but recurrence occurred. The etiology, symptoms, diagnosis, treatment, natural evolution and prognosis of cystitis glandularis are discussed.
Collapse
Affiliation(s)
- P Mast
- Sint-Jozefkliniek, Oostende
| | | |
Collapse
|
9
|
Oosterlinck W, Mast P. Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review. Acta Urol Belg 1994; 62:67-71. [PMID: 8197932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Once hormone resistance has been developed in metastasized prostate cancer, the main aim of therapy is to ensure quality of life. Total androgen blockade which neutralizes the androgens of adrenal origin provides a therapeutic modality which gives +/- 16% objective and +/- 50% subjective response during several months. The two drugs actual available in Belgium are flutamide and cyproterone acetate. Especially flutamide has been used for this purpose. As the number and intensity of side effects is low, this can be considered as a first choice treatment when prostate cancer escapes its first line therapy.
Collapse
|
10
|
Mast P, Vereecken L, Van Loon C, Hermans M. Actinomycosis of the ano-rectum: a rare infectious disease mimicking carcinomatosis. Acta Chir Belg 1991; 91:150-4. [PMID: 1862683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Abdominal actinomycosis is an infectious disease caused by Actinomyces israeli, a usual germ of the gastro intestinal tract. It gives unusual tumoral lesions with abcesses and fistulas. More rarely is abdominal actinomycosis at the end of the abdominal tube. Cope in 1949 said: "Actinomycosis occurs so seldom in the colon and the rectum that no surgeon, even if he be a proctologist is likely in a life time to see more than a few cases" (4). An anorectal actinomycosis case that looked like rectal cancer is reported. It was treated successfully by surgery and antibiotherapy. Some anatomopathologic and mainly histologic characteristics lead to the diagnosis. General and pathological aspects, symptoms, diagnosis, differential diagnosis and therapy of anorectal actinomycosis are discussed.
Collapse
Affiliation(s)
- P Mast
- Dienst Heelkunde, A.Z. St. Vincentius, Gent
| | | | | | | |
Collapse
|